Идёт набор NCT06989112

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

Фаза III С лечением Endometrial Cancer

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают: В протоколе указаны: Trastuzumab deruxtecan, Rilvegostomig, Pembrolizumab, Carboplatin.
Кому может быть актуально: Состояния в реестре: Endometrial Cancer. Базовые параметры: от 18 лет · Женщины.
Что важно проверить: Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится: США, Австралия, Австрия, Бельгия, Бразилия +18
Следующий шаг: Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

DESTINY-Endometrial01: An Open-Label, Sponsor-Blinded, Randomized, Controlled, Multicenter, Phase III Study of Trastuzumab Deruxtecan (T-DXd) Plus Rilvegostomig or Pembrolizumab vs Chemotherapy Plus Pembrolizumab as First-Line Therapy of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer

Обзор

DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression free survival (PFS), as assessed by BICR, in participants with HER2-expressing (IHC 3+/2+), pMMR, primary advanced (Stage III/IV) or recurrent EC.

Вмешательства

Препарат Trastuzumab deruxtecan
Experimental therapy by intravenous infusion
Препарат Rilvegostomig
Experimental therapy by intravenous infusion
Препарат Pembrolizumab
Immunotherapy by intravenous infusion
Препарат Carboplatin
Standard of Care (SoC) chemotherapy by intravenous infusion
Препарат Paclitaxel
Standard of Care (SoC) chemotherapy by intravenous infusion
Препарат Docetaxel
Standard of Care (SoC) chemotherapy by intravenous infusion

Первичные конечные точки

Progression-free survival (PFS), as assessed by BICR [Срок оценки: Until progression or death due to any cause (assessed up to approximately 45 months).]

Вторичные конечные точки (12)

Overall Survival (OS) [Срок оценки: Until the date of death due to any cause (assessed up to approximately 70 months).]
Progression Free Survival (PFS) as assessed by the investigator [Срок оценки: Until progression or death due to any cause (assessed up to approximately 70 months).]
Time from randomization to second progression or death (PFS2) [Срок оценки: Until the earliest of the progression event (following the initial investigator-assessed progression), after first subsequent therapy, or death (assessed up to approximately 70 months).]
Objective response rate (ORR), as assessed by BICR and investigator [Срок оценки: Until progression or the starting of subsequent anticancer therapy (assessed up to approximately 45 months).]
Duration of response (DoR), as assessed by BICR and investigator [Срок оценки: Until progression or death due to any cause (assessed up to approximately 45 months).]
Safety and tolerability [Срок оценки: Safety is assessed until the 90 days (+7) after the last dose (assessed up to approximately 70 months).]
Pharmacokinetics of T-DXd, total anti-HER2 antibody, DXd and rilvegostomig [Срок оценки: Up to safety follow-up period (assessed up to approximately 45 months).]
Immunogenicity of T- DXd and rilvegostomig [Срок оценки: Up to safety follow-up period (assessed up to approximately 45 months).]
Patient-reported tolerability [Срок оценки: Up to progression as assessed by BICR (assessed up to approximately 45 months).]
Progression-free survival (PFS) according to MMR status to determine the clinical utility of a MMR diagnostic test [Срок оценки: Through completion of study, assessed up to approximately 70 months.]
Overall survival (OS) according to MMR status to determine the clinical utility of a MMR diagnostic test [Срок оценки: Through completion of study, assessed up to approximately 70 months.]
Progression-free survival (PFS) according to HER2 expression to determine the clinical utility of a HER2 diagnostic test [Срок оценки: Through completion of study, assessed up to approximately 70 months.]

Критерии участия

Key Inclusion Criteria:

Participants must be ≥ 18 years of age at the time of screening. Other age restrictions may apply as per local regulations.
Histologically confirmed diagnosis of epithelial endometrial carcinoma. All histologies are allowed except for sarcomas (carcinosarcomas are allowed).
Following surgery or diagnostic biopsy, participant must have primary advanced disease (Stage III/IV) or first recurrent endometrial cancer and meet at least one of the following criteria:

Primary Stage III (per FIGO 2023) disease with measurable disease at baseline per RECIST 1.1 based on the investigator's assessment.
Primary Stage IV disease (per FIGO 2023) regardless of presence of measurable disease at baseline.
First recurrent disease regardless of presence of measurable disease at baseline.
Endometrial cancer with HER2 IHC expression of 3+ or 2+ as assessed by prospective central testing.
Endometrial cancer that is determined pMMR by prospective central IHC testing.
Provision of adequate FFPE tumor tissue sample of a tumor lesion that was not previously irradiated for central HER2, MMR, and PD-L1 IHC testing and valid central test results for randomization/ stratification.
Prior therapy:

Naïve to first-line systemic anticancer therapy. Participants may have received one prior line of adjuvant/neoadjuvant chemotherapy with curative intent (chemotherapy or chemoradiation) if disease recurrence or progression occurred ≥ 6 months after last dose of chemotherapy. Prior trastuzumab in the adjuvant/neoadjuvant setting is allowed.
No prior exposure to ADCs or immune checkpoint inhibitors including (but not limited to) anti-PD-1/PD-L1/PD-L2 and anti-CTLA-4 antibodies and therapeutic anticancer vaccines.
Participants may have received prior radiation therapy for the treatment of endometrial cancer. Prior radiation therapy may have included pelvic radiation therapy, extended field pelvic/para-aortic radiation therapy, and/or intravaginal brachytherapy. Adequate treatment washout period is required.
Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1.
Left ventricular ejection fraction (LVEF) ≥ 50% within 28 days before randomization.
Adequate organ and bone marrow function within 14 days before randomization.
Key Exclusion Criteria:

History of organ transplant
Uncontrolled intercurrent illness, including, but not limited to ongoing or active known infection, serious chronic gastrointestinal conditions associated with diarrhea and active non-infectious skin disease requiring systemic treatment.
Spinal cord compression or clinically active central nervous system metastases
Participants with a medical history of myocardial infarction (MI) within 6 months before randomization, or symptomatic congestive heart failure (CHF) (NYHA Class II to IV), clinically significant arrhythmia, or cardiomyopathy of any etiology. Participants with troponin levels above ULN at screening (as defined by the manufacturer), should have a cardiologic consultation before enrollment to rule out MI
History of (non-infectious) ILD/pneumonitis that required steroids, current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
Lung criteria:

Lung-specific intercurrent clinically significant illnesses including, but not limited to, any underlying pulmonary disorder (e.g., pulmonary emboli within 3 months of the study enrollment, severe asthma, severe chronic obstructive pulmonary disease (COPD), restrictive lung disease, pleural effusion etc.).
Any autoimmune, connective tissue or inflammatory disorders where there is documented, or a suspicion of pulmonary involvement at the time of screening.
Prior pneumonectomy (complete).
Active or prior documented autoimmune or inflammatory disorders requiring chronic treatment with steroids or other immunosuppressive treatment.
Active primary immunodeficiency/ active infectious disease(s) including:

Tuberculosis (TB)
HIV infection that is not well controlled.
Chronic or active hepatitis B, chronic or active hepatitis C; however, participants who have chronic hepatitis B and are receiving suppressive antiviral therapy are allowed to be enrolled if alanine aminotransferase (ALT) is normal and viral load is controlled.
Any concurrent anticancer treatment without an adequate washout period prior to the first dose of study intervention. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., HRT) is allowed.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение: Рандомизированное
Модель: Параллельные группы
Маскирование: Открытое
Основная цель: Лечение